Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Although favorable demographics and the launch of innovative new products will drive continued growth in the US market for skin replacements and substitutes, challenges in the biologic product segment, with some private insurers ceasing to cover higher-priced amniotic allografts, will hinder market expansion to some extent.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for skin replacements and substitutes in the US across a 10-year period.
Amniotic-derived allografts have experienced rapid adoption in the biologic skin replacement and substitute segment.
Which companies have benefited most from the adoption of these products?
How has this shift in product preference affected the traditional allograft market?
What do physicians have to say about amniotic-derived allografts?
How will recent changes in some private insurers' coverage policy affect the amniotic-derived allograft market?
Reimbursement changes in the US have affected payment for skin replacements and substitutes.
What is the current reimbursement system for skin replacements and substitutes?
What are some strategies company can employ to receive favorable reimbursement?
Product launches, acquisitions, and partnerships represent key competitive strategies in this space.
Which competitors are launching new products and in which segments?
How will Smith & Nephew's acquisition of Osiris Therapeutics affect the market?
How are partnerships and acquisitions helping smaller companies compete with more established competitors?
Clinical data are of utmost importance to physicians when choosing skin replacements and substitutes.
Why do physicians feel so strongly about clinical data when it comes to skin replacements and substitutes?
Which companies are investing in clinical trials?
How have results from recent clinical trials affected company performance?
Already a Client? Log in to access this report.
Monica Lin is an analyst within the Orthopedics, Dental, and Aesthetics Medtech Insights team at Decision Resources Group, focusing on the sports medicine, spinal implant, vertebral compression fracture treatment, and skin replacement and substitute markets. Monica holds an Honors Bachelor's degree in Life Physics and Economics from the University of Waterloo.